Trial start Phase 2: A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia source ↗
Raise Private equity round — Series A: $77.5M (total, as published), announced Mar 17, 2026. Source: company release on GlobeNewswire. source ↗
Upcoming milestones
Feb 28, 2027 (ESTIMATED) · Phase 2 · A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia · NCT06712654
Estimated primary completion per ClinicalTrials.gov. Dates move.
Funding
Raised: $77.5M. Last 2 years.
Private equity round — Series A: $77.5M (total, as published), announced Mar 17, 2026. Source: company release on GlobeNewswire. source ↗
